Development of vaccines against autologous tumor-derived idiotypes in human myeloma: Rationale and preparation

Minerva Biotecnologica

Volumn 8, Issue 1, 1996, Pages 1-8

  Battaglio, Silvano ^b   Napoli, Patrizia ^b   Beggiato, Eloise ^b   Borrione, Paolo ^b   Ciaiolo, Carlo ^b   Peola, Silvia ^b   Bianchi, Alberto ^b   Stiefel, Thomas ^a   Boccadoro, Mario ^b   Pileri, Alessandro ^b   Massaia, Massimo ^b,c  

^a Biosyn Arzneimittel GmbH   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c Dipto di Med e Oncol Sperimentale Div Universitaria di Ematologia   (Italy)

Author keywords

Multiple myeloma; Vaccines

Indexed keywords

EID: 0013640661     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Boccadoro M, Pileri A. Standard chemotherapy for myelomatosis: an area of great controversy. Hematol Oncol Clin North Am 1992;6:371-82.
2. Alexanian R, Haut A, Khan AU et al. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
3. Mandelli F, Avvisati G, Amadori S. Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-4.
4. Hoover RG, Kornbluth J. Immunoregulation of murine and human myeloma. Hematol Oncol Clin North Am 1992;6:407-24.
5. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med 1983;308:314-6.
6. Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood 1978;51:1005-11.
7. Joshua DE, Wearne A, Kronenberg H. Immunoregulation and prognosis in myeloma. Lancet 1987;ii:251-3.
8. Osteborg A, Steinitz M, Lewin N et al. Establishement of idiotype bearing B-lymphocyte clones from a patient with monoclonagammopathy. Blood 1991;78:2642-9.
9. Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD. Studies on the clonal origin of multiple myeloma. J Exp Med 1979;150:798-807.
10. Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin (IgG) and IgA-secreting multiple myeloma. J Exp Med 1993;178:1091-6.
11. Massaia M, Pileri A. T cells in multiple myeloma: is this a reliable population to count on as antitumor effector cells? Leukemia and Lymphoma 1995;17:63-70.
12. Dianzani U, Pileri A, Boccadoro M et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988;72:1064-8.
13. Massaia M, Bianchi A, Attisano C et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 1991;78:1770-80.
14. Massaia M, Attisano C, Peola S et al. Rapid generation of anti-plasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 1993;82:1787-97.
15. Janson CH, Grunewald J, Osterborg A et al Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 1991;77:1776-80.
16. Osterborg A, Masucci MS, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H. Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monclonal gammopathy. Cancer Immunol Immunother 1991;34: 157-62.
17. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 1992;13:74-6.
18. Lanzavecchia A. Identifying strategies for immune interventions. Science 1993;260:937-42.
19. Russell JH, White CL, Low DY, Meleedy-Rey P. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 1991;88:2151-5.
20. Massaia M, Borrione P, Attisano C et al. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 1995;85-3679-87.
21. Omede P, Boccadoro M, Gallone G et al. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990;76: 1375-9.
22. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotypic vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 1987;138: 1289-96.
23. Jorgensen T, Gaudernack G, Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma proteins 315 inhibits growth of mouse plasmacytoma MOPC-315. Scand J Immunol 1980;11:29-37.
24. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophopshamide. J Immunol 1988; 141:3227-33.
25. Daley MJ, Gebel HM, Lynch RG. Idioytpe-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J Immunol 1978;120:1620-4.
26. Bridges SH. Partecipation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol 1978;121:479-83.
27. Freedman PM, Autry JR, Tokuda S, Williams RC. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst 1976;56:735-40.
28. Sugai S, Palmer DW, Talal N, Witz IP. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous Iymphoma of NZB/NZWF1 mice. J Exp Med 1974;140:1547-58.
29. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol 1983;130:970-3.
30. George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in the suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987;138:628-34.
31. Kwak L, Campbell MJ, Zelenetz AD, Levy R. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood 1990;76:2411-7.
32. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Development of a new therapeutic approach to B cell malignancy: the induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol 1989;4:251-9.
33. George AJT, Folkard SG, Hamblin YJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988;141:2168-74.
34. Kresina TF, Baine Y, Nisonoff A. Adoptive transfer of resistance to growth of an idiotype-secreting hybridoma by T cells from idiotypically suppressed mice. J Immunol 1983;130:1478-82.
35. Audibert FM, Lise DL. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993;14:281-4.
36. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci 1989;86:4240-3.
37. Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine induced protection. J Immunol 1988;140: 294-9.
38. Good MF, Pombo D, Lunde MN et al. Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. J Immunol 1988;141:972-7.
39. Kawakura H, Rosenberg SA, Berzofsky JA. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med 1985;162:381-6.
40. Meuer SC, Dumann H, Buschenfelde KHM, Kohler H. Low-dose interleukin 2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989;i:15-8.
41. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139:1113-9.
42. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epiderma Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988;167:700-5.
43. Fisher HG, Frosch S, Reske K, Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988;141:3882-8.
44. Smith PD, Lamerson CL, Wong HL, Wahl LM, Wahl SM. Granulocye-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol 1990; 144:3829-34.
45. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-8.
46. Grabstein K, Mochizuki D, Kronheim S et al. Regulation of antibody production in vitro by granulocyte-macrophage colony stimulating factor. J Mol Cell Immunol 1986;2:199-208.
47. Kwak LW, Campbell MJ, Czerwinsky D, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-15.